Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hectorol Dosing Conversion from Zemplar in SHPT
NCT00463021Phase 4Completed
- Sponsor
- Sanofi
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of doxercalciferol in secondary hyperparathyroidism (SHPT) (3 arms), sponsored by Sanofi. Primary endpoint: Dose Conversion Factor at 10 weeks. Started Apr 2007; status: completed.
02
Drugs
doxercalciferol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00463021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00463021.